Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Barbara Ann Karmanos Cancer Institute
With
National Cancer Institute (NCI)
OBJECTIVES:
Primary
* Evaluate the use of 3'-deoxy-3'-\[18F\] fluorothymidine (FLT) positron emission tomography (PET) imaging to measure tumor proliferation and the DNA synthetic pathway (thymidine kinase levels) in patients with cancer.
Secondary
* Determine the efficacy of FLT PET imaging in detecting lesions and estimating response to treatment.
OUTLINE: Patients undergo up to four 3'-deoxy-3'-\[18F\] fluorothymidine positron emission tomography imaging procedures.
Age
18–120
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
DISEASE CHARACTERISTICS:
Meets one of the following criteria:
* Histologically confirmed solid tumor or hematologic malignancy
* Awaiting biopsy or surgery for cancer evaluation of a mass detected on exam or standard imaging
PATIENT CHARACTERISTICS:
Able to lie still in the PET scanner
Girth and weight must be suitable to enter the gantry
